Lord’s Mark Secures HIV Self‑Test Approval, Begins Exports June 2026
In a move that places it among a select group of global players, Lord’s Mark Industries Ltd. has received Central Licensing Authority approval for its LordsMed HIV 1&2 Self Test. The licence, numbered MFG/IVD/2023/000058, authorises the company to manufacture and export a Class D in‑vitro diagnostic self‑test for private use. Exports will start in June 2026, opening doors to markets across Africa, the European Union and South America.
Why the Approval Matters
HIV self‑testing has become a cornerstone of public health strategies worldwide. By allowing individuals to check their status at home, it reduces barriers to diagnosis, speeds up treatment initiation and supports efforts to curb transmission. In many regions, especially where access to clinical laboratories is limited, self‑tests are a vital tool for expanding coverage.
India’s regulatory framework for medical devices, set out in the Medical Devices Rules of 2017, classifies in‑vitro diagnostics into four categories. Class D covers devices intended for self‑testing, which must meet stringent safety and performance criteria before they can be sold or exported. Gaining clearance in this category signals that the product has passed rigorous evaluation.
Lord’s Mark Industries Ltd.: A Brief Overview
Founded in 1991, Lord’s Mark Industries has grown into a diversified conglomerate with interests in chemicals, textiles, and pharmaceuticals. The company’s healthcare division has focused on diagnostics, developing a portfolio that includes rapid tests for malaria, typhoid and HIV. The recent approval of the LordsMed HIV 1&2 Self Test adds a significant new product to this lineup.
Product Highlights: LordsMed HIV 1&2 Self Test
The test is designed for private use, enabling individuals to collect a sample, perform the assay and interpret the result without professional assistance. It detects both HIV‑1 and HIV‑2 antibodies, providing a single, convenient solution for users. While the source material does not detail the test’s performance metrics, the Class D clearance indicates that it meets the required accuracy and reliability standards set by the Central Licensing Authority.
Regulatory Pathway in India
India’s Central Licensing Authority (CLA) is responsible for granting licences to manufacturers of medical devices. The CLA evaluates applications against the Medical Devices Rules, ensuring that devices are safe, effective and meet quality standards. For in‑vitro diagnostics, the CLA issues licences that specify the device’s intended use, classification and permissible markets.
The licence number MFG/IVD/2023/000058 reflects the approval process that began in 2023. By 2026, the product will be ready for export, marking a milestone for the company and for India’s diagnostic industry as a whole.
Global Market Landscape
HIV self‑testing is experiencing rapid growth in regions where traditional testing services are scarce or stigmatized. Africa, for instance, has seen a surge in demand for self‑tests as part of national HIV prevention programmes. The European Union has also embraced self‑testing, offering regulatory pathways that facilitate market entry for compliant devices. South America, with its diverse health systems, presents a mix of opportunities for decentralized diagnostics.
Lord’s Mark’s entry into these markets aligns with a broader shift toward self‑administered diagnostics. By providing a reliable, easy‑to‑use product, the company can support health authorities in reaching populations that might otherwise remain undiagnosed.
Implications for the Indian Diagnostics Industry
India is a major producer of medical devices, and its exports have grown steadily over the past decade. The approval of the LordsMed HIV 1&2 Self Test adds to the country’s reputation for manufacturing high‑quality diagnostics at competitive prices. It also demonstrates the effectiveness of India’s regulatory system in fostering innovation while maintaining safety standards.
For other Indian manufacturers, Lord’s Mark’s success may serve as a benchmark. The company’s experience navigating the CLA’s requirements could inform best practices for future product development and regulatory submissions.
Looking Ahead: Export Roll‑Out
Starting in June 2026, Lord’s Mark will begin shipping the LordsMed HIV 1&2 Self Test to key international markets. While the exact volume of exports is not yet disclosed, the company’s strategic focus on Africa, the EU and South America suggests a targeted approach that aligns with regional demand patterns.
As the product enters these markets, it will likely undergo additional post‑market monitoring to capture real‑world performance data. This information can feed back into product improvement and help maintain confidence among healthcare providers and consumers alike.
Key Takeaways
- Lord’s Mark Industries Ltd. has secured Central Licensing Authority approval for its LordsMed HIV 1&2 Self Test.
- The product is a Class D in‑vitro diagnostic self‑test for private use, cleared under India’s Medical Devices Rules of 2017.
- Exports will commence in June 2026, targeting Africa, the EU and South America.
- The approval places the company among nine global players with Class D clearance for HIV self‑tests.
- India’s regulatory framework supports the development of reliable, affordable diagnostics for global markets.
Lord’s Mark’s milestone reflects a broader trend toward decentralized testing, offering individuals worldwide a convenient option to know their HIV status. The company’s upcoming export launch will bring this innovation to new regions, potentially expanding access to early diagnosis and treatment.
